Clinical trials: Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS
The FUNCtion Amyotrophic Lateral Sclerosis (ALS) trial is a randomized, double-blind, placebo-controlled Phase 1/2 trial to evaluate the safety and tolerability of TRCN-1023 in adults living with ALS.
- Trial name
- FUNCtion ALS (NCT07674667)
- Testing
- TRCN-1023
- Where
- 6 sites in Germany, Netherlands and 1 more
- Volunteers
- 30 people
- Sponsor
- Trace Neuroscience, Inc.
Amyotrophic Lateral Sclerosis
Ultra-high-caloric, Fatty Diet in ALS
This study aims at evaluating efficacy and tolerability of an ultra-high-caloric, fatty diet (UFD) compared to placebo in patients with amyotrophic lateral sclerosis (ALS).
- Trial name
- LIPCAL-ALS II (NCT06280079)
- Testing
- Ultra-high-caloric fatty diet
- Where
- 23 sites in Germany
- Volunteers
- 399 people
- Sponsor
- University of Ulm
Amyotrophic Lateral Sclerosis (ALS)
Study of COYA 302 for the Treatment of ALS
The ALSTARS trial will be conducted across 20-25 sites in the US and Canada, and will evaluate the safety and efficacy of an investigational treatment called COYA 302 for adults with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- ALSTARS (NCT07161999)
- Testing
- COYA 302
- Where
- 25 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Coya Therapeutics
Amyotrophic Lateral Sclerosis
A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS
Amyotrophic lateral sclerosis (ALS) is a progressive neurological disorder characterized by selective death of upper and lower motor neurons, which leads to severe disability and fatal outcomes.
- Trial name
- NCT06249867
- Testing
- Darifenacin 7.5 MG Extended Release Oral Tablet
- Where
- 2 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Oliver Blanchard
Tetraplegia/Tetraparesis, Amyotrophic Lateral Sclerosis (ALS)
Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of an implantable device that records and stimulates different areas of the brain to allow adults affected by disabling paralysis (see Eligibility…
- Conditions
- Tetraplegia/Tetraparesis, Amyotrophic Lateral Sclerosis (ALS), Muscular Disorders, Atrophic, Brain Stem Stroke
- Trial name
- INTENT (NCT07521930)
- Testing
- INTENT Neural Interface System
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Johns Hopkins University
Amyotrophic Lateral Sclerosis (ALS)
Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregivers?
Amyotrophic lateral sclerosis (ALS) is a fatal, rare neurodegenerative disease affecting 30,000 people in the United States. The gold standard of care for people with ALS is multidisciplinary clinics (MDC).
- Trial name
- VITALS (NCT07454733)
- Testing
- Video recording, Notes Instruction
- Where
- 7 sites in United States
- Volunteers
- 800 people
- Sponsor
- Trustees of Dartmouth College
Stroke, Parkinson Disease
PhiCube for Bilateral Upper Limb Neuromotor and Cognitive Rehabilitation in Adults
This randomized controlled pilot trial evaluates the usability and safety of PhiCube, a compact, portable, bilateral end-effector robotic device for upper limb rehabilitation, and its impact on motor and cognitive function.
- Conditions
- Stroke, Parkinson Disease, Amyotrophic Lateral Sclerosis, Spinal Cord Injuries
- Trial name
- PhiCube-Adults (NCT07865260)
- Testing
- PhiCube, Conventional rehabilitation
- Where
- 4 sites in Italy
- Volunteers
- 80 people
- Sponsor
- Istituto di Sistemi e Tecnologie Industriali Intelligenti per il Manifatturiero Avanzato
Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP)
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American…
- Conditions
- Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD)
- Trial name
- NCT04363684
- Where
- 26 sites in United States, Canada
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Amyotrophic Lateral Sclerosis
Early Access Program for Ulefnersen in Children, Adolescents and Adults With FUS-associated Amyotrophic Lateral Sclerosis (FUS-ALS)
This expanded access program provides access to ulefnersen for eligible patients with FUS-associated amyotrophic lateral sclerosis (FUS-ALS) who meet protocol-defined eligibility criteria.
- Trial name
- NCT07862959
- Testing
- Ulefnersen
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Amyotrophic Lateral Sclerosis, Cognitive Impairment
Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen in Norway: A Prospective Cohort Study
This study evaluate use of a translated Norwegian version of the Edinburgh cognitive and behavioral amyotrophic lateral sclerosis screen (ECAS-N) as an early predictor in car-driving, working and use of advanced life-prolonging…
- Trial name
- NCT03578796
- Testing
- ECAS-N, MoCA, CDR
- Where
- Norway
- Volunteers
- 31 people
- Sponsor
- Haukeland University Hospital
Amyotrophic Lateral Sclerosis
Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS
Phase II/III multicenter, randomized, double-blind, placebo-controlled trial on acetyl-L-carnitine (ALCAR) in subjects living with amyotrophic lateral sclerosis (ALS).
- Trial name
- ALCALS (NCT06126315)
- Testing
- Acetyl-l-carnitine
- Where
- 19 sites in Australia, Italy
- Volunteers
- 246 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
ALS (Amyotrophic Lateral Sclerosis), MND (Motor Neurone DIsease)
A Programme for Amyotrophic Lateral Sclerosis Care in Europe
Amyotrophic Lateral Sclerosis (ALS) or else known as Motor Neurone Disease (MND) is a rapidly progressive fatal neurological disease that strikes in the prime of life, and for which there is no treatment.
- Trial name
- ALS-CarE (NCT03081338)
- Where
- United Kingdom
- Volunteers
- 73 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Amyotrophic Lateral Sclerosis
The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS.
Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The average survival from the time of diagnosis is 3 years. Apart from Riluzole, there is no effective treatment.
- Trial name
- NCT04562831
- Testing
- EH301 (Nicotinamide Riboside/Pterostilbene)
- Where
- 9 sites in Norway
- Volunteers
- 380 people
- Sponsor
- Haukeland University Hospital
Amyotrophic Lateral Sclerosis
TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis
This trial adopts a multicenter, randomized, double-blind, placebo-controlled parallel design. This experiment is divided into two groups: the experimental drug group and the placebo group.
- Trial name
- NCT06726577
- Testing
- TP04HN106, Saline
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Talengen Institute of Life Sciences, Shenzhen, P.R. China.
Paralysis; Quadriplegic, Quadraplegia
MindEx: A Novel, Multifocal, Cognitive Brain-Machine Interface System
This research study is being done to develop a novel brain-computer interface (BCI) technology that can enable severely paralyzed individuals to interact with the world through direct brain-control of a computer.
- Conditions
- Paralysis; Quadriplegic, Quadraplegia, Tetraplegia, Tetraplegic Motor Dysfunction Following Brainstem or Spinal Cord Injury
- Trial name
- NCT05936619
- Testing
- Mind Extender (MindEx)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Nader Pouratian
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)
Background: Amyotrophic lateral sclerosis (ALS) is a disorder that damages nerve cells in the brain and spinal cord. It can cause muscle weakness, paralysis, and loss of movement. The symptoms grow worse over time.
- Trial name
- NCT07204977
- Testing
- Acamprosate calcium
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis (ALS), Motor Neurone Disease (MND)
Metabolism and Nutrition in MND
Motor neurone disease (MND) is a progressive neurological condition that can affect movement, speech, swallowing and breathing. Weight loss and malnutrition are common in people with MND and may be caused by factors including…
- Trial name
- MET-MND (NCT07851714)
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Amyotrophic Lateral Sclerosis Type 4, Inherited Neurological Disorders of RNA Processing
Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing
Background: Amyotrophic lateral sclerosis type 4 (ALS4) is an inherited motor neuron disease. People with ALS4 have a change in the amount of RNA and DNA that bind together.
- Trial name
- NCT04394871
- Where
- United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis
A Study to Evaluate, Safety, Tolerability, and PK of AP-101 in Participants With ALS
The purpose of this study is to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with fALS and sALS.
- Trial name
- NCT05039099
- Testing
- AP-101
- Where
- 13 sites in United States, Belgium and 4 more
- Volunteers
- 73 people
- Sponsor
- AL-S Pharma
Amyotrophic Lateral Sclerosis
RAPA-501 Therapy for ALS
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
- Trial name
- NCT04220190
- Testing
- RAPA-501 Autologous T stem cells
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Rapa Therapeutics LLC